Alimta®
Pemetrexed is a multi-targeted antifolate used in the treatment of non-small cell lung cancer and malignant pleural mesothelioma. It inhibits multiple folate-dependent enzymes involved in nucleotide synthesis.
| Dosage Form | IV Injectable (Lyophilized Powder) |
| Strength | 100 mg, 500 mg vials |
| Storage | Store at 25°C. Reconstituted solution stable for 24 hours at 2–8°C. |
| Category | Oncology |
| Availability | Available for Transfer |
Non-squamous NSCLC (initial treatment with cisplatin; maintenance); malignant pleural mesothelioma (with cisplatin).
Inhibits thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT), disrupting folate-dependent metabolic processes essential for cell replication.
Each Burrard Pharmaceuticals technology transfer package for Pemetrexed includes comprehensive documentation and support:
Complete formulation with manufacturing parameters, excipient specifications, and process controls.
Validated methods for assay, impurities, dissolution, and stability-indicating analysis.
Market-ready regulatory dossier templates — available through Burrard Intelligence subscription.
ICH-compliant stability studies (accelerated and long-term) with detailed protocols.
Scale-up procedures, batch records, equipment specifications, and in-process controls.
Direct advisory access to formulation scientists and regulatory specialists throughout transfer.
Our team can deliver the complete know-how package within 2–21 business days. Book a consultation to discuss your specific requirements.